Sort by
Keyphrases
Regorafenib
100%
Risk Outcomes
100%
Patient Outcomes
100%
Risk-benefit
100%
Patient Benefit
100%
Drug Development
100%
Clinical Trials
100%
Patient Risk
100%
Urologists
50%
Quality Management
50%
Surgical Quality
50%
Urology Residents
50%
Publication Trends
50%
Residency
50%
Medical Students
50%
Vaccine Misinformation
50%
Coronavirus Disease 2019 Vaccine
50%
Web Search
50%
Infertility
50%
Knee Osteoarthritis
50%
United States
50%
Surgical Management
50%
Meta-analysis
50%
Systematic Meta-analysis
50%
Quality of Life
50%
Filter Migration
50%
Duodenal Perforation
50%
Inferior Vena Cava Filter
50%
Microcytic Anemia
50%
Helminth Infection
50%
Drug Manufacturer
34%
Parasitic Infection
33%
Objective Response Rate
27%
Embase
27%
Colorectal Cancer
24%
Overall Survival
24%
Selective Reporting
20%
Ovid
20%
AMSTAR
20%
Tolerability
17%
In Cancer
17%
New Indication
17%
Pooled Analysis
17%
PubMed
17%
Novel Chemotherapy
17%
Drug Efficacy
17%
Median Progression-free Survival
17%
Adverse Event Rates
17%
Oncologic
17%
Solid Cancer
17%
Pharmacology, Toxicology and Pharmaceutical Science
Regorafenib
100%
Clinical Trial
100%
Drug Development
100%
Observational Study
50%
Coronavirinae
50%
Disease
50%
Microcytic Anemia
50%
Helminthiasis
50%
Malignant Neoplasm
48%
Pharmaceutical Manufacturing
34%
Adverse Event
31%
Overall Survival
24%
Progression Free Survival
24%
Colorectal Carcinoma
24%
Female Infertility
20%
Chemotherapy
17%
Tolerability
17%
Ascariasis
16%
Hookworm Infection
16%
Albendazole
16%
Messenger RNA
10%
Solid Malignant Neoplasm
7%
Pea
7%
